2017 •
Perspectives On Use Of Bevacizumab In Patients With Neuroendocrine Tumors. Case Report
Authors: G. S. Emelianova, N. F. Orel, V. A. Gorbunova, A. A. Kolomeytseva, A. A. Kuznetsova, A. E. Kuzminov, A. A. Fedenko
Venue: Siberian journal of oncology
Type: Publication
Abstract: Advanced well differentiated neuroendocrine tumors (NET) have poor sensitivity to chemotherapy. Biotherapy and targeted therapy are the main treatment options for these patients. Approaches to the 2nd and subsequent lines of treatment have not been developed to date. VEGFR blocker bevacizumab is actively studied in well differentiated NET. For well differentiated NET, it has been shown that an increase in VEGF expression is associated with metastasis and decrease in progression-free survival.
Popularity: This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the
underlying citation network.
Influence: This indicator reflects the overall/total impact of an article in the research community at large, based on the
underlying citation network (diachronically).
Citation Count: This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in
the research community at large, based on the underlying citation network (diachronically).
Impulse: This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation
network.
We have placed cookies on your device to help make this website and the services we offer better. By using this site, you agree to the use of cookies. Learn more